BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in Immunology ; 13 (2022). - Art.-Nr. 920210. - eISSN 1664-3224
- Schlagwort
-
COVID-19
mRNA-Impfstoff
Immunreaktion
- Ereignis
-
Veröffentlichung
- (wo)
-
Ulm
- (wer)
-
Universität Ulm
- (wann)
-
2022
- Urheber
-
Jahrsdörfer, Bernd
Proffen, Matthias
Scholz, Judith
Hägele, Janina
Ludwig, Carolin
Vieweg, Christiane
Grempels, Aline
Fabricius, Dorit
Lotfi, Ramin
Körper, Sixten
Adler, Guido
Schrezenmeier, Hubert
- DOI
-
10.18725/OPARU-44643
- URN
-
urn:nbn:de:bsz:289-oparu-44719-1
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:42 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jahrsdörfer, Bernd
- Proffen, Matthias
- Scholz, Judith
- Hägele, Janina
- Ludwig, Carolin
- Vieweg, Christiane
- Grempels, Aline
- Fabricius, Dorit
- Lotfi, Ramin
- Körper, Sixten
- Adler, Guido
- Schrezenmeier, Hubert
- Universität Ulm
Entstanden
- 2022
Ähnliche Objekte (12)
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein